ATE466928T1 - Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram- negativen bakterien - Google Patents
Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram- negativen bakterienInfo
- Publication number
- ATE466928T1 ATE466928T1 AT00942996T AT00942996T ATE466928T1 AT E466928 T1 ATE466928 T1 AT E466928T1 AT 00942996 T AT00942996 T AT 00942996T AT 00942996 T AT00942996 T AT 00942996T AT E466928 T1 ATE466928 T1 AT E466928T1
- Authority
- AT
- Austria
- Prior art keywords
- gram
- peptidoglycan
- negative bacteria
- lipid
- preparation
- Prior art date
Links
- 101710178358 Peptidoglycan-associated lipoprotein Proteins 0.000 title abstract 4
- 241000894006 Bacteria Species 0.000 title abstract 3
- 102100029989 SHC SH2 domain-binding protein 1 Human genes 0.000 abstract 3
- 239000013612 plasmid Substances 0.000 abstract 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 abstract 1
- 108010013639 Peptidoglycan Proteins 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14106199P | 1999-06-25 | 1999-06-25 | |
PCT/US2000/017020 WO2001000790A1 (en) | 1999-06-25 | 2000-06-20 | Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE466928T1 true ATE466928T1 (de) | 2010-05-15 |
Family
ID=22493991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00942996T ATE466928T1 (de) | 1999-06-25 | 2000-06-20 | Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram- negativen bakterien |
Country Status (15)
Country | Link |
---|---|
US (2) | US7452715B1 (de) |
EP (1) | EP1192242B1 (de) |
JP (1) | JP4660043B2 (de) |
KR (1) | KR100833364B1 (de) |
CN (1) | CN1192101C (de) |
AT (1) | ATE466928T1 (de) |
AU (1) | AU782566B2 (de) |
BR (1) | BR0011804B1 (de) |
CA (1) | CA2370887A1 (de) |
DE (1) | DE60044352D1 (de) |
DK (1) | DK1192242T3 (de) |
ES (1) | ES2343304T3 (de) |
IL (1) | IL146895A0 (de) |
MX (1) | MXPA01013253A (de) |
WO (1) | WO2001000790A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716480B (zh) | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
KR101408113B1 (ko) | 2005-06-27 | 2014-06-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 제조 방법 |
EP1746103A1 (de) * | 2005-07-20 | 2007-01-24 | Applied NanoSystems B.V. | Bifunktionelle Protein-Anker |
JPWO2008105142A1 (ja) * | 2007-02-28 | 2010-06-03 | 日本電気株式会社 | マトリックス溶液 |
US8466259B2 (en) | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
TWI376385B (en) * | 2007-12-07 | 2012-11-11 | Nat Health Research Institutes | Production of lipidated proteins in e. coli |
TWI409275B (zh) | 2009-06-22 | 2013-09-21 | Nat Health Research Institutes | 脂質化腫瘤相關抗原及其免疫治療的組成物及方法 |
TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
CN103468704B (zh) * | 2012-11-06 | 2015-01-07 | 中山大学 | 肽聚糖结合蛋白BjApextrin2及其基因、生产方法和应用 |
CN102925447B (zh) * | 2012-11-06 | 2014-04-02 | 中山大学 | 肽聚糖结合蛋白BjApextrin1及其基因、生产方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340888C (en) | 1988-09-01 | 2000-02-01 | Algis Anilionis | Vaccines and diagnostic assays for haemophilus influenzae |
ATE312934T1 (de) * | 1995-06-07 | 2005-12-15 | Univ Washington | Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit |
JP4139561B2 (ja) * | 1997-12-05 | 2008-08-27 | ユーロペーイシェ ラボラトリウム フュール モレキュラーバイオロジー(イーエムビーエル) | 新規dnaクローニング方法 |
-
2000
- 2000-06-20 CA CA002370887A patent/CA2370887A1/en not_active Abandoned
- 2000-06-20 WO PCT/US2000/017020 patent/WO2001000790A1/en active Search and Examination
- 2000-06-20 BR BRPI0011804-4A patent/BR0011804B1/pt not_active IP Right Cessation
- 2000-06-20 DE DE60044352T patent/DE60044352D1/de not_active Expired - Lifetime
- 2000-06-20 CN CNB008094233A patent/CN1192101C/zh not_active Expired - Fee Related
- 2000-06-20 AT AT00942996T patent/ATE466928T1/de not_active IP Right Cessation
- 2000-06-20 AU AU57534/00A patent/AU782566B2/en not_active Ceased
- 2000-06-20 DK DK00942996.0T patent/DK1192242T3/da active
- 2000-06-20 ES ES00942996T patent/ES2343304T3/es not_active Expired - Lifetime
- 2000-06-20 JP JP2001506784A patent/JP4660043B2/ja not_active Expired - Fee Related
- 2000-06-20 IL IL14689500A patent/IL146895A0/xx unknown
- 2000-06-20 MX MXPA01013253A patent/MXPA01013253A/es active IP Right Grant
- 2000-06-20 US US10/019,164 patent/US7452715B1/en not_active Expired - Fee Related
- 2000-06-20 KR KR1020017016321A patent/KR100833364B1/ko not_active IP Right Cessation
- 2000-06-20 EP EP00942996A patent/EP1192242B1/de not_active Expired - Lifetime
-
2008
- 2008-10-20 US US12/254,251 patent/US7741076B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2001000790A9 (en) | 2009-12-23 |
BR0011804A (pt) | 2002-03-19 |
JP2003503043A (ja) | 2003-01-28 |
EP1192242B1 (de) | 2010-05-05 |
CA2370887A1 (en) | 2001-01-04 |
DE60044352D1 (de) | 2010-06-17 |
JP4660043B2 (ja) | 2011-03-30 |
CN1192101C (zh) | 2005-03-09 |
DK1192242T3 (da) | 2010-07-26 |
AU782566B2 (en) | 2005-08-11 |
BR0011804B1 (pt) | 2011-11-01 |
EP1192242A1 (de) | 2002-04-03 |
WO2001000790A1 (en) | 2001-01-04 |
US7452715B1 (en) | 2008-11-18 |
IL146895A0 (en) | 2002-08-14 |
KR20020039270A (ko) | 2002-05-25 |
KR100833364B1 (ko) | 2008-05-28 |
CN1358227A (zh) | 2002-07-10 |
AU5753400A (en) | 2001-01-31 |
US20090060952A1 (en) | 2009-03-05 |
US7741076B2 (en) | 2010-06-22 |
MXPA01013253A (es) | 2002-06-04 |
ES2343304T3 (es) | 2010-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE466928T1 (de) | Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram- negativen bakterien | |
Reddy et al. | Binding between outer membrane proteins of nontypeable Haemophilus influenzae and human nasopharyngeal mucin | |
Chen et al. | Salmonella‐mediated tumor‐targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model | |
Poole et al. | Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine | |
EP0841941A4 (de) | Neuartige nicht pyrogene bakterienstämme und ihre verwendung | |
Hacker et al. | Cloned hemolysin genes from Escherichia coli that cause urinary tract infection determine different levels of toxicity in mice | |
Byrd et al. | Lactoferrin inhibits or promotes Legionella pneumophila intracellular multiplication in nonactivated and interferon gamma-activated human monocytes depending upon its degree of iron saturation. Iron-lactoferrin and nonphysiologic iron chelates reverse monocyte activation against Legionella pneumophila. | |
Gilleland Jr et al. | Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection | |
Chai et al. | Two bacteriophages which utilize a new Escherichia coli major outer membrane protein as part of their receptor | |
IL75277A (en) | Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gramnegative bacteria,pharmaceutical formulations composing them and lyphocyte cell lines secreting them | |
PT2351579T (pt) | Vacinas polipeptídicas para proteção ampla contra linhagens meningocócicas hipervirulentas | |
Judd | 125I-peptide mapping of protein III isolated from four strains of Neisseria gonorrhoeae | |
BR9708387A (pt) | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. | |
Jacques et al. | Adhesin–receptor interactions in Pasteurellaceae | |
MX9708438A (es) | Proteina principal de la membrana externa de moraxella, de alto peso molecular. | |
RU94046291A (ru) | Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i | |
EP0692031A4 (de) | Heterologe antigene in stämmen zur impfung mit lebendzellen | |
ES8600649A1 (es) | Un metodo de producir una forma geneticamente estable de vidrio cholerae | |
Cohen et al. | Mucosal infection with Neisseria gonorrhoeae. Bacterial adaptation and mucosal defenses. | |
Shiau et al. | Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis | |
DK0851926T3 (da) | Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet | |
Al‐Bader et al. | Activation of human dendritic cells by the PorA protein of Neisseria meningitidis | |
Kishimoto et al. | A new interleukin with pleiotropic activities | |
FI102189B1 (fi) | Menetelmä tippuribakteerin PIA-proteiinin tuottamiseksi ja eristämiseksi | |
EP0400569B1 (de) | Verfahren zur Herstellung eines Antikaries-Impfstoffes aus Streptococcus mutans und Impfzusammensetzung gegen Karies in Form von Nasentropfen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |